Free Trial

Opthea (OPT) Competitors

Opthea logo
$3.41 +0.23 (+7.23%)
As of 07/3/2025

OPT vs. AGIO, CGON, KNSA, BEAM, IDYA, IRON, BLTE, CNTA, HRMY, and ADPT

Should you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Agios Pharmaceuticals (AGIO), CG Oncology (CGON), Kiniksa Pharmaceuticals International (KNSA), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Harmony Biosciences (HRMY), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry.

Opthea vs. Its Competitors

Agios Pharmaceuticals (NASDAQ:AGIO) and Opthea (NASDAQ:OPT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Agios Pharmaceuticals has a net margin of 1,798.26% compared to Opthea's net margin of 0.00%. Opthea's return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals1,798.26% -2.75% -2.52%
Opthea N/A N/A N/A

In the previous week, Agios Pharmaceuticals had 2 more articles in the media than Opthea. MarketBeat recorded 5 mentions for Agios Pharmaceuticals and 3 mentions for Opthea. Opthea's average media sentiment score of 0.92 beat Agios Pharmaceuticals' score of 0.33 indicating that Opthea is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Agios Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Opthea
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Agios Pharmaceuticals has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Opthea has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.

Agios Pharmaceuticals currently has a consensus price target of $58.60, suggesting a potential upside of 66.43%. Opthea has a consensus price target of $1.33, suggesting a potential downside of 60.90%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Agios Pharmaceuticals is more favorable than Opthea.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agios Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
Opthea
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.17

56.0% of Opthea shares are held by institutional investors. 4.9% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 3.2% of Opthea shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Agios Pharmaceuticals has higher revenue and earnings than Opthea.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agios Pharmaceuticals$36.50M55.87$673.72M$11.243.13
Opthea$120K4,373.61-$220.24MN/AN/A

Summary

Agios Pharmaceuticals beats Opthea on 8 of the 15 factors compared between the two stocks.

Get Opthea News Delivered to You Automatically

Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OPT vs. The Competition

MetricOptheaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$524.84M$2.91B$5.52B$9.02B
Dividend YieldN/A2.44%5.24%4.08%
P/E RatioN/A20.3027.1920.04
Price / Sales4,373.61250.76395.22100.83
Price / CashN/A41.7026.2128.59
Price / Book-6.097.397.925.55
Net Income-$220.24M-$55.04M$3.17B$248.49M
7 Day PerformanceN/A2.51%1.79%4.87%
1 Month PerformanceN/A-0.21%1.28%6.63%
1 Year Performance73.98%3.41%33.32%20.38%

Opthea Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OPT
Opthea
0.3642 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
+80.4%$524.84M$120K0.008Gap Up
AGIO
Agios Pharmaceuticals
3.9556 of 5 stars
$35.21
-2.4%
$58.60
+66.4%
-17.4%$2.09B$36.50M3.13390
CGON
CG Oncology
2.3347 of 5 stars
$26.25
-2.4%
$58.67
+123.5%
-17.7%$2.05B$1.14M-17.3861Gap Down
KNSA
Kiniksa Pharmaceuticals International
3.3882 of 5 stars
$27.95
+0.3%
$38.80
+38.8%
+44.4%$2.03B$423.24M-111.80220Positive News
Analyst Upgrade
BEAM
Beam Therapeutics
2.4749 of 5 stars
$19.18
-4.1%
$48.75
+154.2%
-16.9%$2.01B$63.52M-4.16510
IDYA
IDEAYA Biosciences
2.3661 of 5 stars
$21.16
-4.3%
$53.73
+153.9%
-38.2%$1.94B$7M-5.8980
IRON
Disc Medicine
3.1366 of 5 stars
$53.38
-2.5%
$96.70
+81.2%
+14.5%$1.90BN/A-13.6230
BLTE
Belite Bio
2.4444 of 5 stars
$58.63
-1.4%
$96.67
+64.9%
+28.9%$1.89BN/A-43.1110
CNTA
Centessa Pharmaceuticals
3.1504 of 5 stars
$13.62
-3.2%
$27.89
+104.8%
+55.8%$1.88B$6.85M-7.52200
HRMY
Harmony Biosciences
4.8251 of 5 stars
$32.24
+0.2%
$53.63
+66.3%
+1.4%$1.85B$714.73M12.31200Positive News
ADPT
Adaptive Biotechnologies
3.4104 of 5 stars
$11.74
-0.5%
$10.57
-10.0%
+231.6%$1.79B$178.96M-12.23790

Related Companies and Tools


This page (NASDAQ:OPT) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners